Novartis

Novartis, a pharmaceutical preparation manufacturing company headquartered in Switzerland, reported total Scope 1, 2, and 3 emissions of approximately 4.38 billion kg CO2e in 2025. This includes about 192.3 million kg CO2e from Scope 1 emissions, approximately 14.9 million kg CO2e from market-based Scope 2 emissions, and roughly 4.17 billion kg CO2e from Scope 3 emissions. In 2024, total emissions were about 4.52 billion kg CO2e, comprising around 210.6 million kg CO2e in Scope 1, approximately 29.8 million kg CO2e in market-based Scope 2, and roughly 4.28 billion kg CO2e in Scope 3. For 2023, the total emissions were about 4.87 billion kg CO2e, with Scope 1 at approximately 251.1 million kg CO2e, market-based Scope 2 at roughly 44.1 million kg CO2e, and Scope 3 at about 4.57 billion kg CO2e.

Novartis is committed to significant climate action, aiming to achieve net-zero greenhouse gas emissions across its value chain by 2040, using a 2022 baseline. This long-term goal includes a commitment to maintain at least 90% absolute Scope 1 and 2 emissions reductions from 2030 through 2040 from the 2022 base year, and to reduce absolute Scope 3 GHG emissions by 90% by 2040 from the same base year.

Near-term targets include becoming carbon neutral in its own operations (Scope 1 and 2) by 2025. This involves reducing combined Scope 1 and 2 (market-based) GHG emissions by 100% by 2025, based on 2016 emissions, and reducing absolute Scope 1 and 2 GHG emissions by 90% by 2030 from a 2022 base year. The company also aims to reduce absolute Scope 3 GHG emissions by 42% by 2030 from a 2022 base year. These targets have been validated by the Science Based Targets initiative (SBTi), with near-term targets classified as consistent with a 1.5°C warming scenario. Novartis has already achieved a 63% reduction in Scope 1 and 2 emissions (from energy) between 2016 and 2023. Additionally, Novartis is a signatory of The Climate Pledge.